Downregulation of p21(WAF1/CIP1) and estrogen receptor α in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA)

Oligonucleotides

Volumn 14, Issue 2, 2004, Pages 147-156

  Jepsen, Jan Stenvang ^a   Pfundheller, Henrik M ^b   Lykkesfeldt, Anne E ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b Exiqon AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY RNA; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; ESTROGEN RECEPTOR ALPHA; LOCKED NUCLEIC ACID; MONOMER; NUCLEIC ACID; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGONUCLEOTIDE; PROTEIN P21; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

CELL CYCLE PROTEINS; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; ESTROGEN RECEPTOR ALPHA; HUMANS; OLIGONUCLEOTIDES, ANTISENSE;

MINK CELL FOCUS-FORMING VIRUS;

EID: 3343018402     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/1545457041526281     Document Type: Article

References (42)

1. AMARZGUIOUI, M., HOLEN, T., BABAIE, E., and PRYDZ, H. (2003). Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31, 589-595.
2. ARZUMANOV, A., WALSH, A.P., LIU, X., RAJWANSHI, V.K., WENGEL, J., and GAIT, M.J. (2001a). Oligonucleotide analogue interference with the HIV-1 Tat protein-TAR RNA interaction. Nucleosides Nucleotides Nucleic Acids 20, 471-480.
3. ARZUMANOV, A., WALSH, A.P., RAJWANSHI, V.K., KUMAR, R., WENGEL, J., and GAIT, M.J. (2001b). Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2′-O-methyl/LNA oligoribonucleotides. Biochemistry 40, 14645-14654.
4. BARTEK, J., VOJTESEK, B., STASKOVA, Z., BARTKOVA, J., KEREKES, Z., REJTHAR, A., and KOVARIK, J. (1991). A series of 14 new monoclonal antibodies to keratins: Characterization and value in diagnostic histopathology. J. Pathol. 164, 215-224.
5. BRAASCH, D.A., JENSEN, S., LIU, Y., KAUR, K., ARAR, K., WHITE, M.A., and COREY, D.R. (2003). RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42, 7967-7975.
6. BRAASCH, D.A., LIU, Y., and COREY, D.R. (2002). Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: Effect of mRNA target sequence and chimera design. Nucleic Acids Res. 30, 5160-5167.
7. CARIOU, S., DONOVAN, J.C., FLANAGAN, W.M., MILIC, A., BHATTACHARYA, N., and SLINGERLAND, J.M. (2000). Down-regulation of p21WAF1/CIP1 orp27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. USA 97, 9042-9046.
8. CHEN, H.X. (2003). Clinical development of antisense oligonucleotides as anti-cancer therapeutics. Methods Mol. Med. 75, 621-636.
9. CROOKE, S.T. (2002). Progress in Antisense Technology: The end of the beginning Methods Enzymol. 313, 3-45.
10. CZAUDERNA, F., FECHTNER, M., DAMES, S., AYGUN, H., KLIPPEL, A., PRONK, G.J., GIESE, K., and KAUFMANN, J. (2003). Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31, 2705-2716.
11. ELAYADI, A.N., BRAASCH, D.A., and COREY, D.R. (2002). Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry 41, 9973-9981.
12. FLUITER, K., TEN ASBROEK, A.L., DE WISSEL, M.B., JAKOBS, M.E., WISSENBACH, M., OLSSON, H., OLSEN, O., OERUM, H., and BAAS, F. (2003). In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res. 31, 953-962.
13. FLUITER, K., TEN ASBROEK, A.L., VAN GROENIGEN, M., NOOIJ, M., AALDERS, M.C., and BAAS, F. (2002). Tumor genotype-specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA polymerase II. Cancer Res. 62, 2024-2028.
14. FRIEDEN, M., CHRISTENSEN, S.M., MIKKELSEN, N.D., ROSENBOHM, C., THRUE, C.A., WESTERGAARD, M., HANSEN, H.F., ORUM, H., and KOCH, T. (2003). Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res. 31, 6365-6372.
15. GRUNWELLER, A., WYSZKO, E., BIEBER, B., JAHNEL, R., ERDMANN, V. A., and KURRECK, J. (2003). Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31, 3185-3193.
16. HANSEN, J.B., WESTERGAARD, M., THRUE, C.A., GIWERCMAN, B., and OERUM, H. (2003). Antisense knockdown of PKC-alpha using LNA-oligos. Nucleosides Nucleotides Nucleic Acids 22, 1607-1609.
17. JANSEN, B., and ZANGEMEISTER-WITTKE, U. (2002). Antisense therapy for cancer - The time of truth. Lancet Oncol. 3, 672-683.
18. JENSEN, B.L., SKOUV, J., LUNDHOLT, B.K., and LYKKESFELDT, A.E. (1999). Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6. Br. J. Cancer 79, 386-392.
19. JEPSEN, J.S., and WENGEL, J. (2004). LNA-antisense rivals siRNA for gene silencing. Curr. Opin. Drug Discov. Devel. 7, 188-194.
20. JEPSEN, J.S., SØRENSEN, M.D., and WENGEL, J. (2004). Locked nucleic acid: A potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides 14, 130-146.
21. KLASA, R.J., GILLUM, A.M., KLEM, R.E., and FRANKEL, S.R. (2002). Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12, 193-213.
22. KOSHKIN, A.A., RAJWANSHI, V.K., and WENGEL, J. (1998a). Novel convenient synthesis of LNA [2.2.1]bicyclo nucleosides. Tetrahedron Lett. 39, 4381-4384.
23. KOSHKIN, A.A., SINGH, S.K., NIELSEN, P., RAJWANSHI, V.K., KUMAR, R., MELDGAARD, M., OLSEN, C.E., and WENGEL, J. (1998b). LNA (locked nucleic acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerization, and unprecedented nucleic acid recognition. Tetrahedron 54, 3607-3630.
24. KURRECK, J. (2003). Antisense technologies. Eur. J. Biochem. 270, 1628-1644.
25. KURRECK, J., WYSZKO, E., GILLEN, C., and ERDMANN, V.A. (2002). Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30, 1911-1918.
26. LABORDA, J. (1991). 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res. 19, 3998.
27. LEBEDEVA, I., and STEIN, C.A. (2001). Antisense oligonucleotides: Promise and reality. Annu. Rev. Pharmacol. Toxicol. 41, 403-419.
28. LIU, J., ESTES, M.L., DRAZBA, J.A., LIU, H., PRAYSON, R., KONDO, S., JACOBS, B.S., BARNETT, G.H., and BARNA, B.P. (2000). Anti-sense oligonucleotide of p21(waf1/cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells. Oncogene 19, 661-669.
29. LYKKESFELDT, A.E., LARSEN, S.S., and BRIAND, P. (1995). Human breast cancer cell lines resistant to pure antiestrogens are sensitive to tamoxifen treatment. Int. J. Cancer 61, 529-534.
30. MARWICK, C. (1998). First "antisense" drug will treat CMV retinitis. JAMA 280, 871.
31. MONO, J.A., DEVIDZE, N., GOODWILLIE, A., and PFAFF, D.W. (2003). Reduction of lipocalin-type prostaglandin D synthase in the preoptic area of female mice mimics estradiol effects on arousal and sex behavior. Proc. Natl. Acad. Sci. USA 100, 15206-15211.
32. OBIKA, S., HEMAMAYI, R., MASUDA, T., SUGIMOTO, T., NAKAGAWA, S., MAYUMI, T., and MANISHI, T. (2001). Inhibition of ICAM-1 gene expression by antisense 2′,4′-BNA oligonucleotides. Nucleic Acids Res. 1 (Suppl.), 145-146.
33. OBIKA, S., NANDU, D., HARI, Y., ANDOH, J., MORIO, K., DOI, T., and IMANISHI, T. (1998). Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2′-O,4′-C-methyleneribonucleosides. Tetrahedron Lett. 39, 5401-5404.
34. OPALINSKA, J.B., and GEWIRTZ, A.M. (2002). Nucleic-acid therapeutics: Basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503-514.
35. ORUM, H., and WENGEL, J. (2001). Locked nucleic acids: A promising molecular family for gene-function analysis and antisense drug development. Curr. Opin. Mol. Ther. 3, 239-243.
36. PARTRIDGE, M., VINCENT, A., MATTHEWS, P., PUMA, J., STEIN, D., and SUMMERTON, J. (1996). A simple method for delivering morpholino antisense oligos into the cytoplasm of cells. Antisense Nucleic Acid Drug Dev. 6, 169-175.
37. PETERSEN, M., and WENGEL, J. (2003). LNA: A versatile tool for therapeutics and genomics. Trends Biotechnol. 21, 74-81.
38. SORENSEN, M.D., KVAERNO, L., BRYLD, T., HAKANSSON, A.E., VERBEURE, B., GAUBERT, G., HERDEWIJN, P., and WENGEL, J. (2002). Alpha-L-ribo-configured locked nucleic acid (alpha-L-LNA): Synthesis and properties. J. Am. Chem. Soc. 124, 2164-2176.
39. STEIN, C.A. (2001). The experimental use of antisense oligonucleotides: A guide for the perplexed. J. Clin. Invest 108, 641-644.
40. VICKERS, T.A., KOO, S., BENNETT, C.F., CROOKE, S.T., DEAN, N.M., and BAKER, B.F. (2003). Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem. 278, 7108-7118.
41. WAHLESTEDT, C., SALMI, P., GOOD, L., KELA, J., JOHNSSON, T., HOKFELT, T., BROBERGER, C., PORRECA, F., LAI, J., REN, K., OSSIPOV, M., KOSHKIN, A., JAKOBSEN, N., SKOUV, J., OERUM, H., JACOBSEN, M.H., and WENGEL, J. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. USA 97, 5633-5638.
42. ZHAO, S., MATSON, S., HERRERA, C.J., FISHER, E., YU, H., and KRIEG, A.M. (1993). Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res. Dev. 3, 53-66.